BACKGROUND: We evaluated the reliability and validity of the Pediatric Functional Assessment of Cancer Therapy-Childhood Brain Tumor Survivor version 2.0 (pedsFACT-BrS; patient version for grade school children aged 7-12 years). METHODS: After translating and cross-culturally adapting it into Korean, the psychometric properties of the pedsFACT-BrS were evaluated in 148 childhood brain tumor survivors (mean age, 9.67 years). Pre-testing was performed in 25 patients. RESULTS: The pedsFACT-BrS showed good symptom coverage and overall user comprehension. Internal consistency was acceptable, with Cronbach's α coefficients ranging from 0.70 to 0.92. The pedsFACT-BrS also demonstrated good convergent and divergent validities when correlated with the Revised Children's Manifest Anxiety Scale and Kovacs' Children's Depression Scale. The pedsFACT-BrS showed good known-group validity and effectively differentiated between clinically distinct patient groups (patient vs. control groups, and among patients having different Karnofsky scores), but offered only partial discrimination of physical well-being (PWB) scores when patients were grouped by treatment type. CONCLUSIONS: Our results indicate that this instrument is reliable and valid and can be used to evaluate the quality of life of Korean childhood brain tumor survivors.
BACKGROUND: We evaluated the reliability and validity of the Pediatric Functional Assessment of Cancer Therapy-Childhood Brain Tumor Survivor version 2.0 (pedsFACT-BrS; patient version for grade school children aged 7-12 years). METHODS: After translating and cross-culturally adapting it into Korean, the psychometric properties of the pedsFACT-BrS were evaluated in 148 childhood brain tumor survivors (mean age, 9.67 years). Pre-testing was performed in 25 patients. RESULTS: The pedsFACT-BrS showed good symptom coverage and overall user comprehension. Internal consistency was acceptable, with Cronbach's α coefficients ranging from 0.70 to 0.92. The pedsFACT-BrS also demonstrated good convergent and divergent validities when correlated with the Revised Children's Manifest Anxiety Scale and Kovacs' Children's Depression Scale. The pedsFACT-BrS showed good known-group validity and effectively differentiated between clinically distinct patient groups (patient vs. control groups, and among patients having different Karnofsky scores), but offered only partial discrimination of physical well-being (PWB) scores when patients were grouped by treatment type. CONCLUSIONS: Our results indicate that this instrument is reliable and valid and can be used to evaluate the quality of life of Korean childhood brain tumor survivors.
Authors: Sundeep R Bhat; Tress L Goodwin; Tasha M Burwinkle; Meagan F Lansdale; Gary V Dahl; Stephen L Huhn; Iris C Gibbs; Sarah S Donaldson; Ruth K Rosenblum; James W Varni; Paul G Fisher Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Jeff A Sloan; Marlene H Frost; Rick Berzon; Amylou Dueck; Gordon Guyatt; Carol Moinpour; Mirjam Sprangers; Carol Ferrans; David Cella Journal: Support Care Cancer Date: 2006-06-23 Impact factor: 3.603
Authors: A E Bonomi; D F Cella; E A Hahn; K Bjordal; B Sperner-Unterweger; L Gangeri; B Bergman; J Willems-Groot; P Hanquet; R Zittoun Journal: Qual Life Res Date: 1996-06 Impact factor: 4.147
Authors: Andrea Marinozzi; Nicolò Martinelli; Manlio Panascì; Francesco Cancilleri; Edoardo Franceschetti; Bruno Vincenzi; Alberto Di Martino; Vincenzo Denaro Journal: Qual Life Res Date: 2009-07-09 Impact factor: 4.147
Authors: Cole Wayant; Kaylea Bixler; Morgan Garrett; Jennifer W Mack; Drew Wright; Matt Vassar Journal: J Adolesc Young Adult Oncol Date: 2021-05-13 Impact factor: 2.223